401 Professional Drive, Suite 280
5 articles with Sirnaomics, Inc.
Sirnaomics Receives FDA Approval of IND for Phase 1 Clinical Trial of Systemic RNAi Therapeutic STP707 for Solid Tumor Treatment
Sirnaomics, Inc. announced today that the company's IND application for a systemic siRNA (small interfering RNA) drug candidate, STP707, received the U.S. Food and Drug Administration (FDA) acknowledgment "Study May Proceed" in patients with advanced solid tumors.
Sirnaomics Ltd., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it has sealed $105 million in a Series E financing.
Sirnaomics Doses First Patient in Phase 2b Study of STP705 for Treatment of Squamous Cell Skin Cancer
Sirnaomics, Inc. today announced dose administration for the first patient in a Phase 2b study of the company's drug candidate, STP705, for the treatment of squamous cell skin cancer in situ (isSCC).
Sirnaomics Doses First Patient in Phase 1 U.S. Clinical Study of STP705 for Treatment of Liver Cancer
Sirnaomics, Inc. announced today dose administration for the first patient in a Phase 1 U.S. clinical study for liver cancer treatment.
Sirnaomics Announces Acceptance of Investigational New Drug Application by China NMPA for Global Multicenter Phase 2b Trial of STP705 Treatment for Skin Squamous Cell Carcinoma
Sirnaomics, Inc., today announced that the China National Medical Product Administration (NMPA) has accepted its Investigational New Drug (IND) application for the company's lead candidate, STP705, for the treatment of skin squamous cell carcinoma in situ (isSCC).